Strategic Partnerships Anthem has established a strategic US partnership with Davos Chemical Corp contributing to a meaningful portion of FY26 sales, indicating a channel-friendly customer acquisition path and potential for co-development or exclusive supply arrangements with other US-based or global partners.

IPO Momentum With a recent IPO and a substantial financing round, Anthem is in an expansionary phase, creating opportunities to position advanced CRO/CDMO services for scale-up programs, propelling demand for process development, analytical chemistry, and regulatory compliance services.

High Growth Strong quarterly profitability growth and a revenue base in the hundreds of millions suggest capacity for larger, multi-year engagements in organic synthesis, process development, and discovery biology, appealing to mid-size to virtual pharma and biotech clients seeking reliable scalability.

Global Outreach Active collaboration with pharma leaders and global clients, coupled with Bengaluru-based operations and a global market focus, indicates cross-border selling opportunities for early discovery through late-stage development services, including regulatory readiness and quality systems.

Quality & Compliance Launch of Veeva Vault Quality indicates a strong emphasis on quality management and regulatory compliance, presenting a compelling value proposition for customers prioritizing audits, GMP/GLP readiness, and streamlined quality documentation across outsourcing programs.